Citi tells investors it’s time to sell Moderna after 600%-plus stock gains

Citi analysts have downgraded Moderna, telling investors that the stock's dramatic rally — gains exceeding 600% — has outpaced what revenue and profit forecasts can reasonably support. The call reflects a valuation concern rather than a verdict on the company's science: at current prices, the market appears to be pricing in expectations that go beyond what near-term earnings projections currently show.

For readers, this is a reminder of how vaccine makers trade on narrative as much as numbers. Moderna's surge was driven by optimism about its pipeline and the durability of its COVID-19 franchise. Citi's view suggests that optimism is now fully reflected in the share price, leaving less room for disappointment.

What to watch: whether upcoming earnings reports and pipeline updates validate the premium, and how other analysts respond to Citi's stance. Divergent ratings often signal a stock at a turning point. None of this is a trading recommendation — it simply illustrates how analyst calls can shape sentiment around high-flying names.